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Purpose: Women bear a disproportionate burden of persistent pain conditions when com-
pared to men. To determine whether the hormonal environment affects the clinical experi-
ence of pain, as measured by the days per month of pelvic pain (DPelvicPM), period pain 
(DPeriodPM), headache (DHeadachePM) or the in vitro EC50 for Interleukin-1β (IL-1β) 
release following TLR4 stimulation with Lipopolysaccharide from Peripheral Blood 
Mononuclear Cells (PBMCs). Findings were stratified according to use or non-use of the 
oral contraceptive pill.
Patients and Methods: Fifty-six women aged 16–35 years, with minimal or severe 
dysmenorrhea, and use or non-use of the OC, were enrolled. Blood was collected on two 
occasions in a single menstrual cycle: Days 1–2 and Days 7–10. Hormonal analysis for 
testosterone, dihydrotestosterone, dehydroepiandrosterone, Androstenedione, 3α- 
Androstanediol, 3β-androstanediol, estradiol, estrone, 17α-hydroxyprogesterone, progester-
one, cortisol and sex-hormone binding globulin was undertaken using ultra-sensitive Liquid 
Chromatography Mass–Spectrometry (LC-MS). PBMCs were exposed to lipopolysaccharide 
(LPS) and the resulting Interleukin-1β output was determined.
Results: Non-users of the OC showed a strongly inverse correlation between a reducing free 
androgen index (FAI) and increasing DPelvicPM (p=0.0032), DPeriodPM (p=0.013), 
DHeadachePM (p=0.041). Non-users of the OC showed a significant increase in 
DPelvicPM (p=0.049) on Days 7–10. Modestly significant associations were found between 
reduced androgens and potentiated LPS-induced IL-1β (lower EC50).
Conclusion: This is the first study to investigate the relationship between the hormonal 
environment and activation of the immune system in young women with dysmenorrhoea- 
related pain conditions. Low androgen levels were consistently associated with increased 
pain. Translational implications for the findings are discussed.
Keywords: pain, testosterone, oral contraceptive pill, dysmenorrhoea, pelvic pain, IL-1β
Introduction
Women bear a disproportionate burden of pain compared with men across the 
majority of pain conditions,1 and ample evidence suggests a role for both the 
hormonal and immune environment in the development of female pain. Before 
puberty, the prevalence of chronic pain conditions is approximately equal in boys 
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and girls.2 However, girls are over-represented by the age 
of 12–14 years, with the presence of persistent pain corre-
lating more closely with the stage of pubertal development 
than with age.3 A major contributor to the disparity in 
chronic pain between girls and boys is the presence of 
dysmenorrhea and abdominal pain.4 Dysmenorrhea fre-
quently predates,5 and is believed to be an etiological 
factor in, the development of chronic pelvic pain in 
women.6
Compelling epidemiological, clinical and experimental 
evidence in both human and animal studies demonstrates 
that increased peripheral and central nervous system 
immune system activity, via Toll-Like Receptors (TLRs), 
is involved in the initiation and maintenance of chronic 
pain conditions.7–9 Our group has already demonstrated 
that immune pathology, including an increase in TLR4 
responsiveness, is present in women affected by dysme-
norrhea-related pelvic pain.10
Toll-like receptors are pattern-recognition receptors on 
the surface of cells which recognise molecular patterns 
typically associated with microbial pathogens, and which 
respond with the release of cytokines including 
Interleukin-1β (IL-1β) that promote inflammation. 
Lipopolysaccharide (LPS) within the cell wall of gram- 
negative bacteria is a potent agonist of TLR4, an antigen 
on immune cells including mononuclear cells in the per-
ipheral blood, and glial cells within the brain and spinal 
cord. Altered TLR inflammatory responses have already 
been demonstrated in visceral medical conditions charac-
terized by persistent pain, such as inflammatory bowel 
disease and painful bladder syndrome.11,12
In our previously published work,10 peripheral blood 
from women with dysmenorrhea-related pelvic pain showed 
significantly enhanced IL-1β release from peripheral blood 
mononuclear cells (PBMCs) following in vitro TLR4 sti-
mulation with lipopolysaccharide, when compared with 
pain-free controls. The present study further investigates 
this cohort of women to determine whether the hormonal 
environment affects the degree of TLR4-induced immune 
activation, or the experience of pelvic pain.
In this study, immune system TLR4-dependent reactiv-
ity is measured by determining the dose of LPS required to 
achieve 50% of maximal IL-1β release response (EC50) 
from peripheral blood mononuclear cells (PBMCs). 
Correlations between the levels of individual steroid hor-
mones and cortisol with the days of pelvic pain per month 
(DPelvicPM)l, the days of period pain per month 
(DPeriodPM)id, and the days of headache per month 
(DHeadachePM), allow an objective assessment of the 
relationship between hormone levels and the subjective 
experience of pain. Correlations between the levels of 
individual steroid hormones with the EC50 allow an 
assessment of the relationship between hormone levels 
and the degree of immune system activation. The self- 
reported number of days of period (DPeriodPM) or pelvic 
pain per month (DPelvicPM), is used as an indicator of 
pelvic pain severity.
We investigate the hypothesis that androgens may be 
protective against the development of chronic pain condi-
tions in women, and discuss the potential role of andro-




This is an observational clinical and laboratory study 
further extending analysis of the patient cohort reported 
by Evans et al10, and approved by the Human Research 
Ethics Committee of the Royal Adelaide Hospital, 
Adelaide, South Australia. HREC/14/RAH/63. RAH 
Approval No. 140,217. The study was conducted in accor-
dance with the Declaration of Helsinki.13 All participants 
below the age of 18 were interviewed in the presence of 
a parent or guardian.
Participants
The target population consisted of girls and women aged 
between 16 and 35 years with either minimal, or severe, 
dysmenorrhea. Participants with minimal dysmenorrhea had 
self-reported pain of between 0 and 3 on an 11-point numerical 
scale14 on the worst day of their menstrual period. At the 
screening visit, participants with severe dysmenorrhea had 
self-reported pain of between 7 and 10 on the 11-point numer-
ical scale on the worst day of their menstrual period. 
Participants were further separated according to use or non- 
use of the oral contraceptive pill (OC). Potential participants 
were identified either when they responded to recruitment 
notices displayed to the general public, which provided a link 
to an anonymous Survey Monkey questionnaire, or through 
a private clinic, Pelvic Pain SA. Eligible participants from the 
general public were offered the opportunity of an initial phone 
interview to provide further information about the study, to 
obtain consent for further participation in the study, and to 
arrange a screening assessment visit with the Principal 
Investigator (PI). Figure 1 shows the Enrolment Flow Chart 
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for study inclusion. Study exclusion criteria (Box 1) ensured 
that women possessing factors that might influence inflamma-
tion, TLR receptor response, the immune system, or the sever-
ity of dysmenorrhea were excluded from the study.
Three hundred and sixty women completed the online 
questionnaire, with 105 women choosing to provide their 
contact details for consideration for study inclusion. Phone 
interview assessment by the Principal Investigator further 
excluded 44 women based on the presence of exclusion 
criteria. Sixty-one women recruited from the general pub-
lic and 5 additional women recruited through Pelvic Pain 
SA, Adelaide, Australia proceeded to the Screening Visit, 
where they underwent a full clinical assessment, and the 
appropriate study group allocation was accurately deter-
mined. Participants below the age of 18 were interviewed 
in the presence of their parent or guardian, who co-signed 
the consent form with the participant. One participant was 
excluded due to previous pregnancy. Thus, a total of 65 
women were enrolled in the study. Nine women were 
excluded during the study due to a high pre-test level of 
C-reactive protein (1), use of marijuana (1), irregular 
menstrual cycles (3), non-attendance for testing (2), insuf-
ficiently severe pain (1), and the development of an unre-
lated neurological illness (1). Fifty-six women satisfied all 
inclusion and exclusion criteria and completed the testing 
procedures.
Invitation to Complete Survey 
Monkey Questionnaire through 
Pelvic Pain SA
5
Clinical Assessment and Group 
Allocation at Pelvic Pain SA
5
Enrolled in Study 
5
Invitation to Complete Survey Monkey 







Clinical Assessment and Group Allocation 
at PARC Clinic
61









Figure 1 Enrolment flow chart for participant recruitment and study inclusion.
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Laboratory Methods
Study Visit Schedule and Specimen Collection
Participants were assessed on two occasions during 
a single menstrual cycle: Days 1–2 and Days 7–10. At 
each study visit, participants attended the Pain and 
Anaesthesia Research Centre (PARC) of the Royal 
Adelaide Hospital, Adelaide, Australia. At their visit, 
participants were asked to confirm the absence of exclu-
sion criteria, report the number of days of period pain 
and pelvic pain per month, and provide a blood sample 
for analysis. The use of anti-inflammatory medications 
was avoided for 5 drug half-lives prior to blood 
sampling.
Analysis of blood samples included: a measurement 
of high-sensitivity C-reactive protein (CRP) to exclude 
the presence of un-recognised pre-test inflammation; 
a quantitative assessment of luteinising hormone (LH) 
and follicle-stimulating hormone (FSH) to confirm base-
line hormonal status on Days 1–2; a quantitative assess-
ment of Sex Hormone Binding Globulin (SHBG) 
(Healthscope Laboratories, Adelaide, Australia) to allow 
later calculation of the Free Androgen Index (FAI) and 
Free Estrogen Index (FEI); and an extended hormonal 
profile analysed as a single batch, using ultra-sensitive 
Liquid Chromatography–Mass Spectrometry (LC-MS) 
(Anzac Research Institute, Sydney, Australia). The hor-
monal analysis included measurement of testosterone (T), 
dihydrotestosterone (DHT), dihydroepiandrosterone 
(DHEA), androstenedione (adione), 3α-androstanediol 
(3αdiol), 3β-androstanediol (3βdiol), estradiol (E2), 
estrone (E1), 17α-hydroxyprogesterone (17OHP4), pro-
gesterone (P4) and cortisol (C). Measurements for T, 
DHT, DHEA, adione, 3αdiol, 3βdiol, 17OHP4, P4 and 
C are measured in ng/mL. Measurements for E2 and E1 
are in pg/mL. Our use of high-sensitivity liquid chroma-
tography–mass spectrometry (LCMS) steroid hormonal 
assays overcomes difficulties in androgen research in 
women associated with the low levels of androgens pre-
sent in women compared to men. Hormonal analysis on 
both Days 1–2 (menstrual phase) and Days 7–10 (mid 
follicular phase) of a single menstrual cycle allows esti-
mates of within-subject variability to be distinguished 
from between-subject and assay variability.
The IL-1β release from PMBCs across a range of con-
centrations of lipopolysaccharide stimulation of TLR4 
receptors was used as a measure of TLR4 immune activation 
(Figure 2) and was determined using the technique devel-
oped by Kwok15,16 and published in detail by Evans et al.10




Immune system TLR4-dependent reactivity is measured 
by determining the dose of LPS required to achieve 
a 50% of maximal IL-1β release response (EC50) from 
peripheral blood mononuclear cells (PBMCs). Statistical 
modelling and a non-linear mixed-effects model approach 
was used to estimate the EC50 for each subject, at each 
testing timepoint.10 Concentration–response curves to LPS 
stimulation were fitted to an Emax model using the Hill 
equation,17 with the slope parameter fixed to 1 to reduce 
the number of parameters to be estimated. The model used 
was of the form:
E ¼ E0 þ
Emax�C
EC50 þ C 
where E0 is the response Y at baseline (absence of dose), 
Emax is the asymptotic maximum dose effect (maximum 
effect attributable to the drug) and EC50 is the concentra-
tion which produces 50% of the maximal effect. Individual 
Emax models were fitted for each subject at each timepoint 
(Days 1–2 or Days 7–10).
All model fitting and all analyses were performed 
using Statistical Analysis Software (SAS v 9.4). 
Box 1 Study Exclusion Criteria
Dysmenorrhoea on Days 1–2 reported as 4–6 on a 10-point 
scale
Menstrual cycle length less than 26 or more than 30 days
Irregular menstrual cycles
Previous pregnancy
Use of reproductive hormones (apart from OC)
Use of levonorgestrel-releasing intrauterine device
Use of thyroxine, insulin or corticosteroids
BMI less than 16 or more than 30
Inflammatory process, surgical procedure or infection in previous 4 
weeks
Renal, hepatic, cardiac or auto-immune disease
Use of immunosuppressant medications
Use of medications affecting TLR responsiveness, including 
amitriptyline and minocycline
Use of analgesics including anti-inflammatory drugs, opioids or 
paracetamol for 5 drug half-lives prior to testing
Use of alcohol for 24 hours prior to testing
Use of opioids or marijuana for 30 days prior to testing
Inability to read or comprehend written information provided
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Starting values were set with Max representing the 
maximum response observed for that participant at 
that timepoint, and Min representing the minimum 
response for that participant at that timepoint. From 
the model, the differences in LS means for contrasts 
of interest were obtained with 95% confidence limits 
and relevant P-values by factor. The statistical analysis 
used is further described in our previous paper by 
Evans et al.10
A lower EC50 represents increased responsiveness 
of PBMCs to stimulation with LPS, a proxy 
measurement for increased immune system activation. 
A higher EC50 represents reduced responsiveness of 
PBMCs and reduced negative regulatory pressure and/ 
or controls.
Determination of Free Androgen Index and Free 
Estrogen Index
The FAI was determined according to the formula: 
FAI = 100*testosterone/SHBG.
The FEI was determined according to the formula: 
FEI = 100*estradiol/SHBG.
Figure 2 IL-1β release (Mean ± SEM) following LPS (TLR4) stimulation (12.5pg·mL to 10µg·mL) of PBMC’s obtained from controls: no OC (red circle, solid line), controls: 
OC (blue square, solid line), dysmenorrhea: no OC (red triangle, dotted line), dysmenorrhea: OC (blue upside down triangle, dotted line), pelvic pain: no OC (red diamond, 
dashed line), and pelvic pain: OC (blue cross, dashed line). A four-parameter logistic dose–response curve has been fitted to each graph; data obtained from Days 1–2 and 
Days 7–10 of each individual’s menstrual cycle.
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Statistical Comparisons
Two-tailed non-parametric Spearman correlations were 
undertaken to determine the p-value and Spearman’s 
Rank Correlation Coefficient (r). Correlations were made 
between the levels of individual hormones, cortisol, the 
FAI, and the FEI, with the days per month of pelvic pain 
(DPelvicPM), period pain (DPeriodPM), headache 
(DHeadachePM), and the EC50 for IL-1β release from 
PBMCs (Tables 1–4). Results were reported according to 
the use or non-use of the OC, and testing on Days 1–2 or 
Days 7–10 of the menstrual cycle.
Results
Participant Recruitment
Three hundred and sixty women completed the online 
Survey Monkey questionnaire. Following application of 
the exclusion criteria, 65 women were enrolled in the 
study. Nine women were excluded during the study due to 
a high pre-test level of C-reactive protein (1), use of mar-
ijuana (1), irregular menstrual cycles (3), non-attendance for 
testing (2), insufficiently severe pain (1), and development 
of an unrelated neurological illness (1). Fifty-six women 
aged between 16 and 35 years, with regular menstrual 
cycles, no previous pregnancy, normal body mass index 
(BMI) and good general health, apart from the presence of 
dysmenorrhea-related pelvic pain, completed the study. 
There were no differences in age (p=0.52), height (p=0.52) 
or weight (p=0.68) of the women in each group (one-way 
ANOVA and Kruskal–Wallis analysis).
Multiple correlations were made between hormone levels, 
pain indices (DPelvicPM, DPeriodPM, DHeadachePM) and 
the EC50 for LPS-induced IL-1β release (EC50)
Table 1 Comparison of Significance (p value) Between Androgen, Estrogen and Cortisol Levels and Days of Pelvic Pain per Month 
(DPelvicPM) According to Day of Testing (Days 1–2 or Days 7–10) and OC Use (No OC, OC, or Combined) Describing Significance 
(p value)
Days 1–2 Days 7–10
No OC OC Combined No OC OC Combined
DPelvicPM
Testosterone 0.17 0.09 0.021* 0.99 0.77 0.85
Androstenedione 0.036* 0.65 0.077 0.52 0.68 0.98
DHEA 0.0018** 0.63 0.019* 0.098 0.89 0.24
Free Androgen Index (FAI) 0.0032** 0.098 0.0026** 0.0058** 0.77 0.26
Estradiol (E2) 0.30 0.45 0.15 0.068 0.049* 0.021*
Free Estrogen Index (FEI) 0.50 0.34 0.72 0.71 0.049* 0.64
Cortisol 0.36 0.18 0.27 0.47 0.35 0.40
Notes: *p ≤ 0.05, **p ≤ 0.01.
Table 2 Comparison of Significance (p value) Between Androgen, Estrogen and Cortisol Levels and Days per Month of Period Pain 
(DPeriodPM) According to Day of Testing (Days 1–2 or Days 7–10 of Menstrual Cycle) and OC Use (No OC, OC, or Combined) 
Describing Significance (p value) and Spearman Coefficient (r Value)
Days 1–2 Days 7–10
No OC OC Combined No OC OC Combined
DPeriodPM
Testosterone 0.24 0.13 0.072 0.85 0.44 0.61
Androstenedione 0.035* 0.65 0.077 0.45 0.87 0.62
DHEA 0.013* 0.81 0.060* 0.33 0.96 0.53
Free Androgen Index (FAI) 0.013* 0.19 0.013* 0.029* 0.79 0.25
Estradiol (E2) 0.37 0.73 0.34 0.20 0.23 0.17
Free Estrogen Index (FEI) 0.98 0.54 0.84 0.74 0.099 0.75
Cortisol 0.72 0.24 0.68 0.63 0.66 0.79
Notes: *p ≤ 0.05.
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Comparison Between Hormonal Levels 
and Days of Pelvic Pain per Month 
(DPelvicPM)
Days 1–2: Women who were non-users of the OC showed 
a significant inverse correlation between the DPelvicPM and 
levels of androstenedione (p=0.036), DHEA (p=0.0018) and 
FAI (p=0.0032) (Table 1, Figure 3). The combined cohort of 
all participants showed a significant inverse correlation 
between the DPelvicPM and levels of testosterone 
(p=0.021), DHEA (p=0.019) and FAI (p=0.0026). 
Days 7–10: Women who were non-users of the OC 
showed a significant inverse correlation between 
DPelvicPM and the FAI (p=0.0058). Women who were 
users of the OC showed a significant positive correlation 
between DPelvicPM and levels of estradiol (p=0.049) or 
the FEI (p=0.049) (Table 1, Figure 4). There was no effect 
of cortisol on DPelvicPM.
Comparison Between Hormonal Levels 
and Days of Period Pain per Month 
(DPeriodPM)
Days 1–2: Women who were non-users of the OC showed 
a significant inverse correlation between DPeriodPM and 
levels of androstenedione (p=0.035), DHEA (p=0.013) and 
FAI (p=0.013) (Table 2, Figure 5). The combined cohort of all 
participants showed a significant inverse correlation between 
DPeriodPM and levels of DHEA (p=0.060) and FAI 
(p=0.013).
Table 3 Comparison of Significance (p value) Between Androgen, Estrogen and Cortisol Levels and Days of Headache per Month 
(DHeadachePM) According to Day of Testing (Days 1–2 or Days 7–10 of Menstrual Cycle) and OC Use (No OC, OC, or Combined) 
Describing Significance (p value)
Days 1–2 Days 7–10
No OC OC Combined No OC OC Combine
DHeadachePM
Testosterone 0.13 0.049* 0.010** 0.54 0.99 0.70
Androstenedione 0.26 0.28 0.095 0.39 0.58 0.91
DHEA 0.14 0.23 0.035** 0.077 0.30 0.047*
Free Androgen Index (FAI) 0.20 0.079 0.041* 0.33 0.15 0.82
Estradiol (E2) 0.61 0.93 0.69 0.78 0.38 0.78
Free Estrogen Index (FEI) 0.88 0.73 0.42 0.92 0.83 0.68
Cortisol 0.87 0.44 0.56 0.71 0.42 0.61
Notes: *p ≤ 0.05, **p ≤ 0.01.
Table 4 Comparison of Significance (p value) Between Androgen, Estrogen and Cortisol Levels and EC50 According to Day of Testing 
(Days 1–2 or Days 7–10 of Menstrual Cycle) and OC Use (No OC, OC, or Combined) Describing Significance (p value) and Spearman 
Coefficient (r Value)
Days 1–2 Days 7–10
No OC OC Combined No OC OC Combined
EC50
Testosterone 0.28 0.71 0.29 0.83 0.042* 0.078
Androstenedione 0.080 0.29 0.044* 0.39 0.28 0.75
DHEA 0.39 0.40 0.23 0.66 0.37 0.81
Free Androgen Index (FAI) 0.20 0.87 0.26 0.44 0.13 0.62
Estradiol (E2) 0.54 0.73 0.26 0.81 0.82 0.64
Free Estrogen Index (FEI) 0.88 0.73 0.42 0.91 0.83 0.68





Notes: *p ≤ 0.05, **p ≤ 0.01.
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Days 7–10: Women who were non-users of the OC 
showed a significant inverse correlation between 
DPeriodPM and FAI (p=0.029).
There was no effect of estradiol, FEI or Cortisol on 
DPeriodPM.
Comparison Between Hormonal Levels 
and Days of Headache per Month 
(DHeadachePM)
Days 1–2: Women who were users of the OC showed 
a significant inverse correlation between DHeadachePM 
Figure 3 Comparison between DPelvicPM and levels of Free Androgen Index according to day of testing (Days 1–2 or Days 7–10) and OC use (No OC, OC, or 
Combined).
Figure 4 Comparison between DPelvicPM and the Estradiol according to day of testing (Days 1–2 or Days 7–10) and OC use (No OC, OC, or Combined).
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and levels of testosterone (p=0.049) (Table 3). The com-
bined cohort of all participants showed a significant 
inverse correlation between DHeadachePM and levels of 
testosterone (p=0.010), DHEA (p=0.035), and FAI 
(p=0.041).
Days 7–10: The combined cohort showed a significant 
inverse correlation between DHeadachePM and DHEA 
(p=0.047).
There was no effect of estradiol, FEI or Cortisol on 
DPeriodPM.
Comparison Between Hormonal Levels, 
Cortisol and EC50 for LPS-Induced IL-1β 
Release (EC50)
Days 1–2: The combined cohort of all participants showed 
a significant positive correlation between the EC50 of LPS- 
induced in vitro IL-1β release (increased responsiveness of 
PBMCs) and androstenedione levels (Table 4).
Days 7–10: Users of the OC showed a significant positive 
correlation between the EC50 of LPS-induced in vitro IL-1β 
release and levels of testosterone (p=0.042). Non-users of the 
OC showed a highly significant positive correlation between 
levels of cortisol and the EC50 of LPS-induced in vitro IL-1β 
release increased (p=0.0011, Spearman’s coefficient r= 
+0.63). Users of the OC showed a highly significant inverse 
correlation between cortisol and the EC50 of LPS-induced 
in vitro IL-1β release (p=0.0080, Spearman coefficient 
r=−0.46) (Table 4, Figure 6).
There was no significant effect of DHEA, estradiol, 
FAI or FEI on EC50.
Comparison of Hormone and Cortisol 
Levels Between Users or Non-Users of 
the OC
A one-way ANOVA with Tukey’s post hoc test was used 
to compare hormone levels in women who were users or 
non-users of the OC on both Days 1–2 and Days 7–10 
(Table 5). In women who use the OC, the pill taken on 
Days 1–2 contains lactose only (lactose pill days). The pill 
taken on Days 7–10 contains ethinylestradiol in combina-
tion with a synthetic progestogen (hormone pill days).
Days 1–2: (lactose pill days) Use of the OC was 
associated with a significantly higher level of SHBG 
(p=0.0001) and cortisol (p=0.0001). Use of the OC was 
associated with a significantly lower level of DHEA 
(p=0.0043) and FAI (p=0.0013). There was no significant 
difference in testosterone, estradiol, or FEI.
Days 7–10: (hormone pill days) Use of the OC was 
associated with a significantly higher level of SHBG 
(p=0.0001) and cortisol (p=0.0001). Use of the OC was 
associated with a significantly lower level of androstene-
dione (p=0.0019), DHEA (0.0281) and FAI (p=0.0001).
Figure 5 Comparison between DPeriodPM and the Free Androgen Index according to day of testing (Days 1–2 or Days 7–10) and OC use (No OC, OC, or Combined).
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There was no significant difference in testosterone, 
estradiol or FEI.
The following hormones were present at levels too low 
for statistical analysis: estrone, progesterone, 17- 
hydroxyprogesterone, 3bdiol and estrone. Levels of DHT 
and 3alpha-androstanediol were not significantly asso-
ciated with alteration in either symptoms or the EC50.
When considering these results overall, lower levels of 
androgenic hormones, and particularly the calculated Free 
Androgen Index, were inversely associated with increasing 
DPelvicPM, DPeriodPM, and DHeadachePM. Higher estra-
diol levels on Days 7–10 (pill days), particularly in OC users, 
were associated with an increase in the DPelvicPM, but not 
the DPeriodPM, DHeadachePM or EC50. Weak associations 
were found between lower levels of androgen activity, and 
a lower EC50 consistent with a mildly enhanced immune 
responsiveness. Strong associations were found between cor-
tisol levels and EC50 on Days 7–10 (pill days), with divergent 
direction of action according to use or non-use of the OC.
Discussion
The Association Between Hormone 
Levels and Pain Symptoms
Multiple lines of evidence18,19 describe the excess of 
chronic pain conditions in females when compared to 
Figure 6 Comparison between EC50 and levels of cortisol according to day of testing (Days 1–2 or Days 7–10) and OC use (No OC, OC, or Combined).
Table 5 Comparison of Means for SHBG, Androgen, FAI, Estrogen, FEI and Cortisol Levels in Users and Non-Users of the OC 
According to Day of Testing (Days 1–2 or Days 7–10 of Menstrual Cycle)
Days 1–2 Days 7–10
No OC OC Users P value No OC OC Users P value
Hormonal Measurement (mean)
SHBG 92.39 159 0.0001** 86.35 147.6 0.0001**
Testosterone 0.19 0.25 0.053 0.23 0.21 0.43
Androstenedione 1.031 0.79 0.085 1.18 0.87 0.0019**
DHEA 7.23 4.64 0.0043** 6.91 4.88 0.028*
FA 0.87 0.53 0.0013** 1.12 0.55 0.0001**
Estradiol 22.21 23.43 0.90 50.94 50.91 0.99
FEI 93.11 54.64 0.087 227.60 158.90 0.13
Cortisol 88.47 162.70 0.0001** 80.49 163.60 0.0001**
Notes: *p ≤ 0.05, **p ≤ 0.01.
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males. Pain research to date has predominantly considered 
ways in which the relative estrogen dominance in females 
may predispose females to chronic pain, as opposed to the 
ways in which the relative androgen dominance in males 
may protect males from these conditions. The physiologi-
cal and potentially therapeutic roles of androgens in 
females has been under-researched. Our research found 
a highly significant inverse relationship between androgen 
levels, particularly a low FAI, and increasing pain symp-
toms, particularly in non-users of the OC. Oral contra-
ceptive use results in both the suppression of testosterone 
production by the ovaries, and the induction of SHBG by 
the liver, with a consequently lower FAI (Figure 3).
Multiple mechanisms of action in both the periphery 
and the central nervous system support an inverse relation-
ship between testosterone levels and pain. Studies of male- 
to-female transgender patients show an increase in chronic 
pain conditions following hormonal transition from an 
androgenic to an estrogenic hormonal environment,20,21 
while female-to-male transgender patients show an 
improvement in pre-existing pain conditions following 
the administration of testosterone. Our research found 
a highly significant association between androgen levels 
and pain symptoms, particularly in women who were non- 
users of the OC, where the ovarian production of testos-
terone is unsuppressed and the production of SHBG within 
the liver is not enhanced.
In patients with Rheumatoid Arthritis, an inflammatory 
condition associated with reduced androgen levels in both 
males and females, there is increased production of proin-
flammatory cytokines within synovial cells.22 Within these 
cells, increased levels of IL-1β, tumour necrosis factor 
(TNF) and Interleukin-6 (IL-6) enhance the activity of 
aromatase,23 resulting in the increased conversion of tes-
tosterone to estradiol, increased levels of estrogen, and 
reduced levels of androgens.22,24–26 The disease- 
modifying effects of anti-TNF medications in patients 
with RA may act through the local enhancement of andro-
gen activity.27
Previous human studies have demonstrated the central 
nature of dysmenorrhea-related pelvic pain, its relationship 
to viscero-visceral hyperalgesia, and its association with 
pain co-morbidities including migraine.28–31 Within the 
dorsal horn of the spinal cord, it has been proposed that 
androgens act in concert with estrogen to increase endo-
genous opioids following a nociceptive stimulus.32 White 
and Robinson proposed that a low testosterone level fails 
to induce sufficient endogenous opioids to dampen pain 
signals.33 Fibromyalgia, a centrally mediated pain condi-
tion, is associated with reduced levels of androgens, and 
a strong association has been found between the days 
where symptoms were severe, and the days where testos-
terone levels were low.34 At the neuronal level, dihydro-
testosterone, a metabolite of testosterone, provides 
neuroprotection against microglial inflammatory responses 
via suppression of TLR4, and inhibition of TNF-alpha and 
IL-1β production.35 Within the brain, Vincent et al36 found 
reduced activation of brain centres associated with des-
cending pain inhibition, including the ventral rostral 
medulla, in healthy women with low androgen levels 
undergoing a cold thermal pain stimulus, despite no varia-
tion in the temperature required to induce pain.
In contrast with the robust association with androgenic 
activity, our research found a modest correlation between 
estradiol levels on Days 7–10 and pain symptoms. Our 
findings are consistent with established clinical practice, 
where lower estrogen OCs or estrogen suppression is pre-
scribed to reduce the frequency or volume of menstrual 
bleeding.37 The oral contraceptive pill has known effec-
tiveness at the level of the uterus: reducing menstrual 
flow,38 and reducing prostaglandin release.39,40 It is yet 
to be determined whether the OC-induced androgen sup-
pression and SHBG induction may have unintended nega-
tive effects on the development of central pain 
sensitization.
The Association Between Hormone 
Levels and EC50 of LPS-Induced IL-1β 
Release from PBMCs
Activation of the innate immune system via TLR4 is known 
to be involved in the initiation and maintenance of chronic 
pain,8,9,41,42 with activation showing as increased respon-
siveness of immune cells to TLR stimulation. Our group has 
already demonstrated an increased responsiveness of 
PBMCs to TLR4 activation with LPS within this group of 
women with dysmenorrhea-related pelvic pain, compared 
to pain-free controls.10 Our finding of a modest association 
between reduced androgen activity and a lower LPS- 
induced IL-1β EC50 (increased immune activation) suggests 
that activation of the immune system via TLR4 comprises 
one factor affecting pain symptoms, but that immune 
mechanisms outside the hormonal environment are also 
involved. It also suggests that the ability of hormonal 
manipulation to manage chronic pelvic pain is limited. 
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Our study found no significant effect of estrogens on EC50. 
This is consistent with the research of Bouman et al43 who 
found that neither estradiol nor progesterone influenced the 
release of cytokines from monocytes in humans. However, 
they did not assess the effect of androgens.
The Association Between Cortisol and  
EC50 of LPS-Induced IL-1β Release from 
PBMCs
Our finding of a highly significant association between 
increased levels of cortisol (a suppressor of inflammation) 
and an increased EC50 of LPS-induced IL-1β release 
(reduced activation of the innate immune system) in non- 
users of the OC is consistent with an inflammation-based 
model of chronic pain. The divergent effect in OC users, 
where higher levels of cortisol were associated with 
a lower EC50 of LPS-induced IL-1β release (increased 
activation of the innate immune system) is a potential 
cause for concern to health care providers, owing to the 
known association between immune activation and chronic 
pain. Our findings are consistent with those of 
Vincent et al44 who described a significantly lower mean 
level of cortisol in women with dysmenorrhea where all 
participants were non-users of the OC, suggesting an 
impairment of the immune response. Use of the OC has 
already been associated with a reduced cortisol response to 
cold-pressor testing and emotional memory responses.45–47
Measurement of the FAI Within Clinical 
Practice
The majority of testosterone within the circulation is 
protein-bound to either SHBG or albumin, leaving 
a relatively small percentage of testosterone in its 
unbound, bioavailable state. While there are multiple 
cellular mechanisms involved, it is the unbound testoster-
one fraction which contributes maximally to its clinical 
effects. The Free Androgen Index (FAI) provides 
a simple and easily calculated estimate of androgen activ-
ity, requiring only a measurement of total testosterone 
and SHBG. FAI results are less reliable as an indicator of 
testosterone activity in populations where SHBG levels 
are below 30nmol/l, such as in males or women with 
Polycystic Ovarian Syndrome, obesity, or insulin 
resistance.48 For these reasons, the Calculated Free 
Testosterone (cFT) is preferred in some laboratories. 
The cFT incorporates albumin levels, and utilises the 
more complex Vermeulen Equation,49 to provide an 
estimate which more closely matches the results obtained 
by dynamic equilibrium testing in these groups. Our 
research excluded women with a BMI > 30, and women 
with irregular menstrual cycles. The FAI is therefore an 
appropriate test within our study population.
Translational Potential
Our key research finding of an inverse association between 
androgen levels and pain symptoms, both within and out-
side the pelvis, offers a new approach to the management 
of pain in women. Multiple androgen-enhancing options 
are already available. Progestogen-only contraceptive 
users avoid the estrogen-induced rise in SHBG associated 
with combined OCs, and Máximo et al50 demonstrated that 
women using progestogen-only contraception have 
a higher pain threshold than women using the combined 
OC. Intrauterine contraceptive devices maintain natural 
ovarian testosterone production by avoiding ovarian sup-
pression, and their estrogen-induced rise in SHBG. When 
considering the further development of OC formulations, 
an optimal OC for a woman with pain might comprise an 
estrogen with minimal induction of SHBG, and 
a progestogen with minimal anti-androgen activity. 
Conservation of the ovaries at the time of hysterectomy 
maintains gonadal production of testosterone in women 
where post-surgical testosterone replacement is not 
anticipated.51
Testosterone therapy is recommended to reduce pain 
perception and fatigue in women with opioid-induced 
androgen deficiency (OPIAD),52 and White et al reduced 
tender points and stiffness in women with fibromyalgia by 
using testosterone gel.33 However, the role of androgen 
replacement in the absence of opioid use in women with 
low androgen levels and chronic pain is less established. 
Where levels of estrogen or progestogen are low, these are 
replaced to conserve bone density and prevent endometrial 
hyperplasia. The supplementation of testosterone to pre-
vent fatigue, improve sexual function, or reduce chronic 
pain, anxiety and low mood, has been under-utilised. In 
women using hormonal replacement, the estrogen-induced 
rise in SHBG may further reduce androgen activity 
through increased testosterone binding.
Optimal testosterone levels for the reduction of pain 
have yet to be determined. Huang et al53 researched the 
effect of increasing doses of testosterone over 24 weeks in 
hysterectomized and oophorectomized women compared 
to placebo. They observed a significant dose–response 
relationship between free testosterone levels and the 
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Psychological General Well-Being Index (PGWBI) score, 
lean body mass, and stair climbing power when compared 
to placebo, but only where supra-physiological levels were 
achieved. Fasting glucose, lipid profile and liver function 
tests remained unchanged from baseline following testos-
terone administration, and did not differ according to dose. 
Their study considers the use of testosterone as 
a pharmacological treatment, rather than a physiological 
replacement. The future development of selective andro-
gen receptor modulators (SARMs) offers the potential of 
androgen effect without the potential side effect of 
virilization.
Our study raises substantial further research questions 
relating to the use of testosterone therapy to reduce pain or 
enhance quality-of-life in women with current endometrio-
sis lesions. The aromatase-mediated conversion of testos-
terone to estradiol within endometriosis lesions has the 
potential to promote lesion growth. The optimal testoster-
one regime for these women, and the potential for testos-
terone to be used in combination with an aromatase 
inhibitor medication to prevent the conversion of testoster-
one to estrogen,54 has yet to be fully explored.
Our study has notable strengths, including the strin-
gent exclusion criteria used, the lack of clinical co- 
morbidities or confounding medications in this young, 
healthy patient group, and the accurate measurement of 
steroid hormones at low levels, using liquid chromato-
graphy–mass spectrometry methods in a single batch. 
Another strength is the sampling at 2 stages of a single 
menstrual cycle in each participant. A potential study 
weakness is the use of blood hormonal assays rather 
than tissue hormonal assays. As shown in the synovial 
fluid of patients with rheumatoid arthritis,55 or the intra-
lesional fluid in women with endometriosis lesions, the 
enzyme aromatase allows a local hormonal concentration 
of estradiol that may be many times greater than blood 
levels.56 Another weakness is the heterogeneity of parti-
cipants within the oral contraceptive group. This group 
includes participants using a range of different oral con-
traceptive formulations for a range of clinical indications.
Conclusion
Our study provides new insights into the way the hormo-
nal environment affects the experience of pain in women, 
using clinical variables that are readily determined in 
a primary care setting: the DPelvicPM, the DPeriodPM, 
and the DHeadachePM. Of the tests undertaken in our 
cohort of young women with normal BMI and regular 
menstrual cycles, the FAI proved to be a consistent indi-
cator of difference.
Our findings support the concept that the female pre-
dominance of chronic pain relates more to the protection 
men receive from higher testosterone levels, than the risk 
women incur from higher estradiol levels. The potential 
for use of the OC to reduce menstrual symptoms, yet 
increase immune activation, with increased potential for 
the development of chronic pain, requires further research. 
If confirmed, this has widespread implications for the 
management of dysmenorrhea-related pelvic pain in 
young women.
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